Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation

• References

• 1 Kirchmaier CM, Pillitteri D. Diagnosis and Management of Inherited Platelet Disorders. Transfus Med Hemother 2010; 37: 237-246.
• 2 Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011; 154: 161-174.
• 3 Kunishima S, Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol 2010; 17: 405-410.
• 4 Savoia A, De Rocco D, Panza E. et al. Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 2010; 103: 826-832.
• 5 Fabris F, Scandellari R, Vettore S, Scapin M, Bizzaro N, Randi ML. Intriguing outcome of JAK2V617F mutation seen in a patient with MYH9-related hereditary macrothrombocytopenia. Thromb Haemost 2010; 104: 858-859.
• 6 Pecci A, Malara A, Badalucco S. et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost 2009; 102: 90-96.
• 7 Zhang Y, Conti MA, Malide D. et al. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. Blood 2012; 119: 238-250.
• 8 Pecci A, Bozzi V, Panza E. et al. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells. Thromb Haemost 2011; 106: 693-704.
• 9 Pecci A, Gresele P, Klersy C. et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116: 5832-5837.
• 10 Canobbio I, Noris P, Pecci A, Balduini A, Balduini CL, Torti M. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost 2005; 3: 1026-1035.
• 11 Nieto M, Calvo G, Hudson I. et al. The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Haematologica 2011; 96: e33-40.
• 12 Kantarjian H, Fenaux P, Sekeres MA. et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28: 437-444.